89Bio Enlivened by Nash success
The company follows Madrigal and Akero with a clinical hit.
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
Amylyx aces launch as tofersen’s big date approaches
Breakeven beckons for Amylyx.